External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors

John J Cuaron, Karyn A Goodman, Nancy Lee and Abraham J Wu*

Abstract

Background: The role of radiation therapy (RT) in the management of gastrointestinal stromal tumors (GIST) is not well described. Here we report our institutional experience for patients with locally advanced or metastatic GIST treated with RT.

Methods: Between 1997 and 2012, 15 patients with 22 GISTs were treated with RT at our center. The median age was 68 (range, 41–86). Fourteen patients had stage IV disease and 1 patient had stage IIIB disease, per the American Joint Committee on Cancer (AJCC), 7th Edition staging. Tumors were in a variety of locations, and were most commonly referred for palliative treatment. Eighteen of 22 tumors were symptomatic. Prior to RT, 14 of 15 patients received systemic therapy in the form of tyrosine kinase inhibitors (TKIs) (n = 11), chemotherapy (n = 4), or both (n = 1). TKIs were used concurrently for nine tumors (40.9%). No tumors were treated with concurrent chemotherapy. Several fractionation schemes were used, most commonly 3 Gy × 10 (n = 8). Local progression-free survival and overall survival were estimated using the Kaplan-Meier method. Acute toxicity was graded per Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Results: The median follow-up was 5.1 months (range, 1.3-28.3). At the time of analysis, 12 patients have died (80%). The estimated 6-month local progression-free survival and overall survival were 57.0% and 57.8%, respectively. Among the 18 symptomatic tumors, at least partial palliation was achieved in 17 (94.4%), and symptoms were completely palliated in eight (44.4%). Treatment was well tolerated, with no Grade 4 or 5 toxicities. There was no Grade ≥3 toxicity associated with concurrent TKI use.

Conclusions: In this largest series to date of GISTs treated with RT, a high rate of palliation was achieved for symptomatic tumors in a cohort of advanced stage, heavily pretreated patients. Treatment was well tolerated, and concurrent use of tyrosine kinase inhibitor therapy was not associated with additional toxicity. While follow-up was short, durable control is possible for some patients, providing evidence that GIST is not universally radioresistant and that RT can provide an important benefit in patients with progressive or metastatic disease.

Keywords: Gastrointestinal stromal tumor, Radiation therapy, Palliation

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with an estimated annual incidence of 6.8 per million in the United States [1] and 10 per million worldwide [2]. The management of GISTs consists of surgical resection for localized and potentially resectable tumors, but more than half of patients that undergo complete resection develop recurrence within 5 years [3] and are often treated with systemic salvage therapy. Imatinib, a selective inhibitor of the KIT protein tyrosine kinase, demonstrates superior activity against most GISTs and has led to a dramatic improvement in progression free survival among patients with advanced or recurrent disease [4-8]. Although initial response rates to biologically targeted agents are excellent, many patients develop resistance or metastatic disease, at which point further treatment options are limited.
Data regarding the use of radiation therapy for these tumors is lacking. Several case reports have indicated that radiation can reduce tumor burden and produce durable local control in locally advanced and metastatic tumors [9-20], but, to our knowledge, a robust analysis of its effect in a cohort of patients has not been performed. To further investigate the role of radiation therapy in the treatment of GISTs, we retrospectively analyzed our institutional experience with patients that had locally advanced or metastatic GISTs treated with radiation therapy.

Materials and methods
Patient and tumor characteristics
Between 1997 and 2012, a total of 15 patients with 22 GISTs were treated with radiation therapy for either a primary tumor or metastatic disease at our center. These patients were retrospectively identified and placed into a database. Patient characteristics, treatment details, and toxicity information were obtained through chart review. This study was carried out as Study of Existing Data-Application for Exemption from IRB/PB Review, and approval was obtained for a waiver from HIPAA authorization and informed consent as per 45 CFR 164.512(i)(2)(ii) and 45 CFR 46.116(d) (waiver WA0552-12).

The median age of patients was 68 years. The majority of patients had metastatic disease at the time of their radiation treatment, and one patient had stage IIIB disease according to the American Joint Committee on Cancer (AJCC) 7th edition staging. The most common reason that patients were referred for radiation therapy was for palliation of symptoms related to progressive disease (18/22, 82%). Symptoms included pain (n = 12), pain with weakness or numbness (n = 2), bleeding (n = 2), pain with lower-extremity edema (n = 1), and partial bowel obstruction and constipation (n = 1). For those patients that did not have symptomatic tumors, the indications for treatment included the prevention of neurological compromise in the spine (n = 3) and attempted preoperative cytoreduction for an unresectable pelvic tumor (n = 1).

Radiation therapy
Radiation therapy consisted of megavoltage x-rays delivered by linear accelerator. Tumors were most often treated with 300 cGy × 10 fractions (n = 8). Other conventional fractionation schemes included 180 cGy × 25 and 200 cGy × 25. Stereotactic body radiation therapy (SBRT), defined as hypofractionation of ≥500 cGy per fraction utilizing image guidance for delivery, was used for 9 tumors (2400 cGy × 1, n = 2; 900 cGy × 3, n = 2; 800 cGy × 3, n = 1; 600 cGy × 5, n = 2; and 500 cGy × 5, n = 2). Three patients were treated with a partial course of 300 cGy × 10 but did not complete their course due to clinical deterioration while on treatment. Conventional opposed photon fields were used in the treatment of 13 tumors (59.1%) and IMRT was used for nine tumors (40.9%) in the abdomen, pelvis, and paraspinal region.

Systemic therapy
Prior to radiation therapy, 14 of the 15 patients received systemic therapy in the form of tyrosine kinase inhibitors (TKIs) (n = 11), chemotherapy (n = 4), or both (n = 1). TKIs that were used prior to radiation therapy included imatinib for all 11 patients, sunitinib in 7 patients, sorafenib in 5 patients, nilotinib in 1 patient and pazopanib in 1 patient. Other systemic agents used before radiation therapy included mesna, doxorubicin, ifosfamide and dacarbazine (MAID) and postoperative mitoxantrone (n = 1), doxorubicin and dacarbazine (n = 1), doxorubicin, paclitaxel and flavopiridol (n = 1), and doxorubicin and vinorelbine (n = 1). Notably, all patients treated with these systemic agents developed progressive disease.

TKIs were used concurrently (imatinib [n = 4], nilotinib [n = 3], sorafenib [n = 1], and sunitinib [n = 1]) with radiation therapy for the treatment of 9 of the 22 tumors, 6 of which (66.7%) were treated with SBRT. No tumors were treated with concurrent chemotherapy.

Follow-up
Patients were assessed weekly while on treatment. Thereafter, patients were seen at variable intervals by a multidisciplinary disease-management team that generally included surgeons, medical oncologists, and radiation oncologists. The median interval between follow-up visits was 5 weeks (range, 2–12). At each on-treatment visit and follow-up visit, toxicity was assessed per Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Effectiveness of palliation was assessed during on-treatment visits and at the time of follow-up. A patient was considered to have partial palliation if there was any appreciable improvement of symptoms after beginning radiation therapy. Complete palliation was defined as the complete resolution of the presenting symptoms after the beginning of radiation therapy.

Follow-up imaging was available for assessment in 17 of the 22 tumors. Initial radiographic response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST). The median time to the first radiographic assessment after radiation therapy was 2.2 months.

Local progression was defined as any clinical or radiographic evidence of tumor growth. Overall survival was defined from the date of the first radiation treatment to the date of death from any cause. Local progression-free survival and overall survival were estimated using the Kaplan-Meier method.

Results
The median follow-up of the entire cohort was 5.1 months (range, 1.4–28.3). At the time of analysis, 12 of the 15
patients (80%) had died. Among the 18 tumors that were symptomatic at presentation and treated with palliative intent, at least partial palliation was achieved in 17 tumors (94.4%). Symptoms were completely palliated in eight tumors (44.4%).

Partial radiographic response was seen in 35.3% (n = 6) of tumors. Stable disease was seen in 52.9% of tumors (n = 9) and progressive disease in 11.8% (n = 2). Among tumors treated with SBRT with radiographic follow up (n = 8), partial response was seen in 62.5% (n = 5), stable disease was seen in 25.0% (n = 2), and progressive disease in 12.5% (n = 1). The estimated 6 month local progression-free survival was 57.0%, shown in Figure 1. Median survival was 6.6 months, and the estimated 6 month overall survival was 57.8%, shown in Figure 2.

Treatment was extremely well tolerated, with only 1 case of Grade 3 toxicity, consisting of diarrhea in a patient who was being treated to the peritoneum. There were no grade 4 or 5 toxicities. Importantly, there were no Grade ≥3 toxicities seen in patients that were concurrently treated with tyrosine kinase inhibitors. Only one patient experienced persistent dysgeusia after receiving 800 cGy × 3 fractions to the cervical spine. All other toxicities eventually resolved.

A summary of the patient cohort, tumor characteristics, treatment indications and characteristics, outcomes, and toxicities is listed in Table 1.

**Discussion**

In our retrospective study, the use of radiation therapy achieved a high degree of palliation with minimal toxicity in a cohort of heavily pretreated patients with symptomatic GISTs.

Although a rare tumor, GIST incidence is increasing [2]. The cell of origin is thought to be the intestinal pacemaker cells of Cajal. Tumors can arise in any location along the gastrointestinal tract but are most commonly confined to the stomach and small intestine. The primary therapy for limited resectable disease is surgical resection. However, recurrence is common, and the 5-year disease-free survival is only 45% after surgery alone [3].

Historically, GISTs have been very poorly responsive to traditional cytotoxic chemotherapeutic agents. The discovery that over 90% of GISTs harbor a mutation in one of two tyrosine kinases (KIT and platelet-derived growth factor receptor, alpha polypeptide [PDGFR-a]) led to the widespread use of biologically targeted agents for relapsed or unresectable disease. Imatinib, a selective inhibitor of the KIT protein tyrosine kinase that was developed to treat chronic myelocytic leukemia, was shown to markedly improve relapse-free survival in GIST patients [4-8] and has since emerged as the primary treatment modality for patients that have unresectable or metastatic disease [21].

Results of a recent ACOSOG Phase II trial also support the use of imatinib in the adjuvant setting for high-risk patients [22] by demonstrating improved overall survival compared with historical controls.

Unfortunately, the development of imatinib resistance has become a problem among patients that experience an initial response. Options for the management of resistant disease include dose escalation of imatinib, or switching to other tyrosine kinase inhibitors, which have shown activity in imatinib-resistant disease [23-25]. However, prognosis...
for these patients remains poor, and progression of disease within the abdomen or at distant sites often causes significant pain and debilitation among a population with a limited lifespan.

For selected patients with focally progressive disease, local therapies such as limited surgical resection [26-29], radiofrequency ablation [30,31], and chemoembolization [32] can provide palliation and durable freedom from progression. Despite clear evidence of benefit from localized therapies, radiation is rarely used in the management of GISTs for either primary or salvage therapy. There appear to be multiple reasons driving this omission. First is the conventional consideration of GISTs as ”radioresistant” tumors, perhaps due to their histological relation to soft-tissue sarcomas, which have a relatively slow clinical responsiveness to radiation therapy [33] Secondly, retrospective case series showing a lack of benefit from radiation therapy in the adjuvant setting after surgical resection of GISTs has further reduced enthusiasm for the use of this modality [34,35]. Thirdly, the location of tumors within the abdomen has also limited the ability to deliver high doses of radiation therapy using conventional techniques, due to the radiosensitivity of surrounding organs. Finally, physicians may be hesitant to temporarily discontinue TKI therapy to administer a course of palliative radiation due to concerns of disease progression at other sites. While simultaneous administration is an option, the increased risk of high-grade dermatologic and mucosal toxicity when other TKIs (targeted against the epidermal growth factor receptor) are used with radiation therapy [36] often deters physicians from recommending concurrent treatment.

Recently, new insights into the vast genetic and molecular heterogeneity of sarcomas, coupled with modern organ-sparing radiation techniques, have challenged the assumptions about radiation therapy in the management of this disease. Several case reports throughout the literature have shown significant clinical and radiographic responses with the use of radiation therapy, with the ability to maintain long-term disease control and palliate bone and visceral metastases in certain cases [9-20]. However, these studies are limited by small patient numbers and the inherent selection and publication biases of single patient reports. In the current study, all patients that were treated consecutively at a single institution were included, making for a more robust analysis, and representing the largest report to date. Results from the current study corroborate previous case reports, as radiation therapy was shown to be highly effective in achieving at least partial palliation in the majority of symptomatic patients. An initial radiographic response was seen in over a third of tumors with adequate follow-up imaging. Toxicities were largely related to the site being treated, were generally mild, and the majority resolved shortly after treatment. In regard to TKI-related toxicity, there were nine tumors that were treated with concurrent tyrosine kinase inhibitor therapy. Among these patients, there were no Grade ≥3 toxicities and no dermatologic toxicities, consistent with previous phase I and II trials demonstrating the safety of concurrent TKI therapy (albeit at a reduced daily dose).

Figure 2 Overall survival. Kaplan-Meier survival curve for overall survival showing median survival: 6.6 months and estimated 6 month overall survival of 57.8%.
Table 1 Patient, tumor, and treatment characteristics

| Age | Sex | Tumor location | Tumor size (SPD) | Indication for RT | Symptoms | Dose of RT (cGy x Fx) | Concurrent TKI* therapy | RECIST* Degree of palliation | Toxicity | Grade | Status at last follow-up |
|-----|-----|----------------|-----------------|-------------------|----------|-----------------------|------------------------|--------------------------|----------|-------|--------------------------|
| 56  | F   | Left flank     | 50.95           | Progression on imatinib | Left flank pain | 300 × 10 Y          | SD                     | Partial                  | Esophagitis           | 2     | A             |
|     |     | Left posterior thorax | 12.22       | Progression on imatinib | Left back pain  | 900 × 3 Y           | PR                     | Partial                  | None                | 0     |               |
|     |     | T12-L1 vertebral bodies | 1.2         | Progression on imatinib | Left back pain | 500 × 5 Y           | PR                     | Partial                  | None                | 0     |               |
| 41  | M   | L3-L5 vertebral bodies | 120         | Progression after multiple surgical resections and systemic chemotherapy | Decreased caliber of stools, right hydronephrosis, groin pain, abdominal pain, and left leg edema | 180 × 25 N          | PD                     | Partial                  | None                | 0     | D             |
| 67  | M   | Abdominal wall  | 45.92           | Progression on nilotinib | Abdominal pain  | 300 × 8 Y           | N/A                    | None                     | Fatigue             | 2     | D             |
| 86  | M   | Abdomen        | 94              | Progression on Phase I experimental targeted agents | Melena, hematemesis | 300 × 10 N          | SD                     | Complete                 | Nausea, fatigue       | 1,1   | A             |
| 73  | M   | L3-S3 vertebral bodies | N/A           | Development of pain while on active surveillance | Left buttock and leg pain | 300 × 9 N          | N/A                    | Complete                 | None                | 0     | D             |
| 74  | M   | T11 vertebral body | 4.14          | Development of epidural disease while on sunitinib | None | 900 × 3 N           | PR                     | N/A                     | None                | 0     | D             |
| 57  | F   | Liver, anterior abdominal wall | 24.91      | Progression on nilotinib and sirolimus | Left abdominal and left flank pain | 600 × 5 Y         | PR                     | Complete                 | None                | 0     | D             |
|     |     | C3-C4 vertebral bodies | 4.44         | Progression on sorafenib | Neck pain, numbness of left shoulder and arm | 800 × 3 Y         | Y                      | Partial                  | Dysgeusia           | 1     |               |
|     |     | C2 vertebral body | N/A            | Progression on nilotinib and sirolimus | None | 600 × 5 Y           | Y                      | N/A                     | None                | 0     |               |
| 71  | M   | Right liver    | 15.12           | Progression on Phase I experimental targeted agents | Shoulder and abdominal discomfort | 2400 × 1 N        | N                     | SD                      | Partial             | 1     | D             |
| 69  | F   | Right ilium and L3 vertebral body | N/A          | Progression of symptoms and inability to tolerate systemic therapy | Low back pain, left sciatica, right leg weakness | 300 × 10 N        | N                     | SD                      | Diarrhea            | 2     | D             |
| 74  | F   | Peritoneum     | 142.3           | Progression on Sorafenib | Radiographic partial bowel obstruction, nausea, dyspepsia, constipation | 300 × 10 N        | Y                     | Partial                  | Nausea, diarrhea     | 1,3   | D             |
| 69  | F   | Foramen magnum to C2 | N/A           | Progression on pazopanib | Severe neck pain radiating to occipital scalp and jaw | 300 × 10 N        | N/A                   | Complete                 | None                | 0     | D             |
|     |     | T12 vertebral body to sacrum | N/A          | Inability to tolerated Phase I experimental targeted therapy | Right buttock and sacral discomfort | 300 × 5 N         | N/A                    | Partial                  | None                | 0     |               |
|     |     | Left hip       | 26.95           | Progression on pazopanib | Left hip pain | 500 × 5 N           | PD                     | Complete                 | None                | 0     |               |

Cuaron et al. Radiation Oncology 2013, 8:274 http://www.ro-journal.com/content/8/1/274
Table 1 Patient, tumor, and treatment characteristics (Continued)

| No. | Sex | Tumor Location | Initial Treatment | Progression | Treatment | RECIST | Response | SD | PD | Alive | Cause of Death |
|-----|-----|----------------|-------------------|-------------|-----------|--------|----------|----|----|-------|----------------|
| 68 F | T2-T7 vertebral bodies | N/A | Progression on taxol/flavopiridol | Mid thoracic back pain | 300 × 10 | N | SD | Complete | Esophagitis | 2 | D |
|     | C1-C4 vertebral bodies | 6.24 | Progression on taxol/flavopiridol | None | 300 × 10 | N | SD | N/A | None | 0 |
| 58 M | Left abdominal mass | 81.78 | Progression on Phase I experimental targeted agents | Hematochezia and hematemesis | 300 × 10 | N | SD | Complete | None | 0 | D |
| 45 F | L2-L3 vertebral bodies | 8.94 | Development of painful symptoms while on imatinib | Lumbar pain exacerbated by sitting | 2400 × 1 | Y | PR | Complete | None | 0 | D |
| 64 M | Pelvis | 118.3 | Attempt for presurgical cytoreduction while on sunitinib | None | 200 × 25 | Y | SD | N/A | Diarrhea, urinary freq/urgency, fatigue | 1, 1 | A |

*SPD sum product diameter, cGy × Fx centigray per fraction, TKI tyrosine kinase inhibitor, RECIST response evaluation criteria in solid tumors, PR partial response, SD stable disease, PD progressive disease, A alive, D deceased.
and radiation therapy for oligometastases [37,38]. The results of the current study suggest that, for those patients that are benefitting from TKI therapy at some sites of disease but progressing at others, concurrent radiation therapy can be safe and effective in helping to control symptoms of pain, weakness, and obstruction. Collectively, these results indicate that radiation therapy can provide both objective responses and symptomatic relief without detracting dramatically from quality of life, and should be considered in the multidisciplinary care of patients with locally advanced or metastatic GISTs.

Our study is limited by its retrospective design. Because the follow-up schedule of the cohort was heterogeneous, conclusions regarding radiographic response and toxicity are limited. Further, the non-uniformity of the radiation doses makes it difficult to analyze dose response and effectiveness of certain dose levels. Finally, the follow-up for the cohort is short, reflecting the poor prognosis of these advanced-stage, heavily pretreated patients. Despite these limitations, the findings remain hypothesis generating and give important insights into a treatment modality that appears to be safe and effective in the management of patients with metastatic or locally advanced GISTs.

Conclusions
This study represents the largest report of patients with locally advanced and metastatic GISTs treated with radiation therapy. Radiation was largely effective at achieving palliation for symptomatic tumors, and radiographic response is possible in some patients, providing evidence that GIST is not universally radioresistant. Toxicities were mild, and concurrent use of TKI therapy did not portend an increased risk of side effects. Further study to establish the role of radiation therapy in the management of gastrointestinal tumors is needed and supported by the findings of this report.

Consent
This study was carried out as Study of Existing Data-Application for Exemption from IRB/PB Review, and approval was obtained for a waiver from HIPAA authorization and informed consent as per 45 CFR 164.512(i)(2)(ii) and 45 CFR 46.116(d) (waiver number WA0552-12).

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JJC participated in the design of the study, carried out the chart review, performed statistical analyses, and drafted the manuscript. KAG and AJW participated in the design of the study and helped to draft the manuscript. NL conceived of the study and participated in the revision of the manuscript. All authors read and approved the final manuscript.

Received: 20 September 2013 Accepted: 20 November 2013 Published: 23 November 2013

References
1. Tran T, Davila JA, El-Serag HB: The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005, 100:162–168.
2. Demetri GD, Von Mehren M, Antonescu CR, DeMatteo RP, Garciou GN, Maki RG, Pisters PW, Rait CP, Riedel RF, Schurtte S, et al: NCCN Task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010, 8(Suppl 5-1): 542–544.
3. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51–58.
4. Blanke CD, Demetri GD, Von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, et al: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIF. J Clin Oncol 2008, 26:620–625.
5. Blanke CD, Rankin C, Demetri GD, Ryan CW, Von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase. J Clin Oncol 2008, 26:626–632.
6. Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472–480.
7. Gastrointestinal Stomal Tumor Meta-Analysis Group: Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010, 28:1247–1253.
8. Verweij J, Casali PG, Zalberg J, LeCesne A, Reichard P, Bley IV, Isels R, Van Oosterom A, Hogeveen PC, Van Glabbeke M, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127–1134.
9. Shoyama Y, Yakeishi Y, Watanabe T, Nakamura K, Kunitake T, Kimura M, Sasai M, Honda H, Terahira H, Natsuda K: Long-term control for a retroperitoneal metastasis of malignant gastrointestinal stromal tumor after chemoradiotherapy and immunotherapy. Acta Oncol 2001, 40:102–104.
10. Mori Y, Kobayashi T, Shibamoto Y: Stereotactic radiosurgery for metastatic tumors in the pituitary gland and the cavernous sinus. J Neurosurg 2006, 105:37–42.
11. Boruban C, Sencan O, Akmanu M, Atik ET, Ozbek S: Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate. Anticancer Drugs 2007, 18:569–572.
12. Cireasa M, D’Angelillo RM, Rameh S, Cellini F, Gaudino D, Stinti G, Fiore M, Greco C, Nudo R, Trodella L: Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report. Tumori 2009, 95:236–239.
13. Hamada S, Iizumi A, Watanabe G, Nakayama S, Tanaka E, Hojo M, Yoshizawa A, Hricot S, Saka Y: Intracranial metastasis from an esophageal gastrointestinal stromal tumor. Intern Med 2010, 49:781–785.
14. Knowlton CA, Brady LW, Heintzelman RC: Radiotherapy in the treatment of gastrointestinal stromal tumor (GIST) of the rectum: a case report. Ann Surg 2007, 245:637–643.
15. Loi L, Pantaleo MA, Nannini M, Saponara M, Pallotti MC, Scioscio VD, Barbieri E, Mandrioli A, Biasco G: Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. Rare Tumors 2011, 3:e49.
16. Naoe H, Kaku E, Ido Y, Gushima R, Maki Y, Saito H, Yokote S, Gushima R, Nonaka K, Hoshida Y, et al: Brain metastasis from gastrointestinal stromal tumor: a case report and review of the literature. Case Rep Gastroent 2011, 5:583–589.
17. Tokuda H, Koshihhi H, Yoshimura T, Kakei M, Ikenouchi A, Chiku N, Nishida K, Okamura T: Twenty-one-year survival case of rectal GIST treated with combined therapies. Gan To Kagaku Ryoho 2011, 38:2205–2207.
18. Chiguchi G, Kawana K, Nagase H, Osima I, Arita T, Matsui S, Kakuta Y, Miyagi Y, Ozaki M: A case of small intestinal stage IV gastrointestinal stromal tumor in which long-term disease control was maintained for more than 10 Years through a multidisciplinary team approach. Gan To Kagaku Ryoho 2012, 39:1898–1901.
19. Halpern J, Kim YJ, Sultana R, Villani G. Effectiveness of radiation therapy in GIST: a case report. J Gastrointest Oncol 2012, 3:143–146.
20. Fujisawa T, Matsunoto Y, Nishizawa A, Takata M. A case of liver and bone metastases after complete resection of gastric GIST effectively treated with radiotherapy and imatinib mesylate. Nihon Shokakibyo Gakkai Zasshi 2013, 110:258–256.
21. Von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU, 3rd, DeLaney TF, Ganjo KN, George S, Gonzalez R, Heslin MJ, et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012, 10:951–960.
22. Dematteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, Von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (alliance) intergroup phase 2 trial. Ann Surg 2013, 258:422–429.
23. Demetri GA, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1120–1138.
24. Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yaqi S, Hsu Y, Gallet I, Rutkowski P. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012, 23:1680–1687.
25. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, Von Mehren M, Joensuu H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:295–302.
26. Raut CP, Posner M, Desai J, Morgan GA, George S, Zahirri D, Fletcher CD, Demetri GD, Bertagnoli MM. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006, 24:2325–2331.
27. Al-Batran SE, Hartmann JT, Heidel F, Stoehlmaeher J, Wardellmann E, Dechow C, Du X, Isbicki JR, Kraus T, Fischer T, Jager E. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer 2007, 10:145–152.
28. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007, 245:347–352.
29. Musi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichard P, Casali PG, Fiore M, Hohenberger P, Gronchi A. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010, 21:403–408.
30. Jones RL, McCall J, Adam A, O'Donnell D, Ashley S, Al-Muderis O, Thway K, Fisher C, Judson IR. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol 2010, 36:477–482.
31. Yamakado K, Takaki H, Nakatsu K, Utaka J, Fujimori M, Hasegawa T, Sakuma H, Yamakado K. Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. J Vasc Interv Radiol 2013, 24:341–346.
32. Kobayashi K, Sakurada H, Trent JC, Ensor J, Ahmar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors. Ann J Clin Oncol 2009, 32:574–581.
33. Strander H, Turesson J, Cavanlin-Stahl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. Acta Oncol 2003, 42:516–531.
34. Crosby JA, Catton CN, Davis A, Couture J, O’Sullivan B, Kandel R, Swallow CJ. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001, 8:50–59.
35. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001, 136:383–389.
36. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009, 115:1286–1299.
37. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA. Phase I study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009, 115:3571–3580.
38. Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer S, Forsythe K, Gendron EM, Schwartz M, Lau KH, et al. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One 2012, 7:e36979.